The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis
Open accessAbstract
BACKGROUND: Observational studies of the ongoing coronavirus disease 2019 (COVID-19) outbreak suggest that a 'cytokine storm' is involved in the pathogenesis of severe illness. However, the molecular mechanisms underlying the altered pathological inflammation in COVID-19 are largely unknown. We report here that toll-like receptor (TLR) 4-mediated inflammatory signaling molecules are upregulated in peripheral blood mononuclear cells (PBMCs) from COVID-19 patients, compared with healthy controls (HC). METHODS: A total of 48 subjects including 28 COVID-19 patients (8 severe/critical vs. 20 mild/moderate cases) admitted to Chungnam National University Hospital, and age/sex-matched 20 HC were enrolled in this study. PBMCs from the subjects were processed for nCounter Human Immunology gene expression assay to analyze the immune related transcriptome profiles. Recombinant proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were used to stimulate the PBMCs and monocyte-derived macrophages, and real-time polymerase chain reaction was performed to quantify the mRNA expressions of the pro-inflammatory cytokines/chemokines. RESULTS: Among the most highly increased inflammatory mediators in severe/critically ill patients, S100A9, an alarmin and TLR4 ligand, was found as a noteworthy biomarker, because it inversely correlated with the serum albumin levels. We also observed that recombinant S2 and nucleocapsid proteins of SARS-CoV-2 significantly increased pro-inflammatory cytokines/chemokines and S100A9 in human primary PBMCs. CONCLUSION: These data support a link between TLR4 signaling and pathological inflammation during COVID-19 and contribute to develop therapeutic approaches through targeting TLR4-mediated inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.017 · Cited by 4,206
Henry, B. M., de Oliveira, M. H. S., Benoit, S., Plebani, M., & Lippi, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0369 · Cited by 1,964
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945
Wang, S., Song, R., Wang, Z., Jing, Z., Wang, S., & Ma, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01298 · Cited by 1,450
Xiong, Y., Liu, Y., Cao, L., Wang, D., Guo, M., Jiang, A., Guo, D., Hu, W., Yang, J., Tang, Z., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1747363 · Cited by 1,076 · cited 1×
“lymphopenia, high neutrophil-to-lymphocyte ratio, and increased inflammatory cytokine and chemokine levels (1, 5, 12-17).”
BackgroundPremkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A. J., Cornaby, C., Bartelt, L., Weiss, S., Park, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc8413 · Cited by 868
Toll-Like Receptor Pathways in Autoimmune Diseases
Chen, J.-Q., Szodoray, P., & Zeher, M. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8473-z · Cited by 315 · cited 1×
“Although both TLR and IL-1 signaling activation is critical for innate immune defense against a variety of pathogens, dysregulation of this signaling pathway can lead to pathogenesis of various diseases including inflammatory and autoimmune diseases (25-28).”
BackgroundChinenov, Y., & Rogatsky, I. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.04.014 · Cited by 133
Bhattacharyya, S., Zhao, Y., Kay, T. W. H., & Muglia, L. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017296108 · Cited by 93
Cited by
Role of Toll‐like receptors in the pathogenesis of COVID‐19
Khanmohammadi, S., & Rezaei, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26826 · Cited by 370
Aboudounya, M. M., & Heads, R. J. (2021) · Mediators of Inflammation · doi:10.1155/2021/8874339 · Cited by 346
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis
Ramasamy, S., & Subbian, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00299-20 · Cited by 289
Metadata
- Authors
- Sohn, K. M., Lee, S.-G., Kim, H. J., Cheon, S., Jeong, H., Lee, J., Kim, I. S., Silwal, P., Kim, Y. J., Paik, S., Chung, C., Park, C., Kim, Y.-S., & Jo, E.-K.
- Venue
- Journal of Korean Medical Science
- Publisher
- XMLink
- Published
- 2020
- Volume
- 35
- Issue
- 38
- Pages
- e343-e343
- ISSN
- 1011-8934 (ISSN-L)
- 1598-6357
- OpenAlex
- W3085500933
- Cited by
- 199
- References
- 14
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.